此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy (KOKORO01)

Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal/reversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

6

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Herault
      • Montpellier、Herault、法国、34298
        • Julien Welmant

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

概率样本

研究人群

Participants will be recruited from the pediatric radiotherapy unit at Montpellier Cancer Institute (ICM).During the initial consultation to initiate radiotherapy treatment at ICM, the investigator physician will present the KOKORO-01 study. They will answer all questions regarding its procedures and will provide the parents or legal representative with the information sheet and consent form. Parents or the legal representative will have at least one week to consider participation, during which they may ask any questions they wish.

描述

Inclusion Criteria:

  1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years.
  2. Child with an indication for radiotherapy treatment at ICM.
  3. Child who speaks French.
  4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent.
  5. Child covered by the French national health insurance system.

Exclusion Criteria:

6. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria

  1. Parent of a child enrolled in the study.
  2. Able to speak French.
  3. Willing to participate in the study. Parent Exclusion Criteria

1. Parents or legal representatives under legal protection, or presenting an inability to consent or to understand the study information, making it impossible to provide free and informed consent for the minor's participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To evaluate the immediate intra-individual effect of MIROKI on a physiological marker of anxiety in children undergoing radiotherapy.
大体时间:During the treatment, across the 6 radiotherapy sessions
The child's anxiety level measured through an objective assessment of heart rate (bpm sensor).
During the treatment, across the 6 radiotherapy sessions

次要结果测量

结果测量
措施说明
大体时间
Evaluate the immediate intra-individual effect of MIROKI in children on: Psychological distress level
大体时间:administered before the start of treatment and after completion of treatment
Distress questionnaire (PedsQL 3.0 Cancer Module score, Varni et al.)
administered before the start of treatment and after completion of treatment
Evaluate the immediate intra-individual effect of MIROKI in children on development of attachment and reassurance
大体时间:Before, during, and after treatment
Daily distress VAS (Peds-DTRS score, Patel et al., 2011, 2021) and standardized real-time observation using an observational grid.
Before, during, and after treatment
Evaluate the satisfaction with care (radiotherapy at ICM) at the end of treatment
大体时间:At the end of treatment
Post-treatment interview (thematic and lexico-metric analysis).
At the end of treatment
Evaluate the impact of MIROKI on the radiotherapy process: Setup time during sessions in the radiotherapy room
大体时间:From the beginning to the end of the treatment course
From the beginning to the end of the treatment course
Evaluate the impact of MIROKI on parents: - Anxiety level - Satisfaction with care at the end of treatment - Experience of the radiotherapy process at the end of treatment
大体时间:Before the start , during and after the treatment,
  • Anxiety score (GAD-7, Spitzer et al., 2006)
  • Parent-child relationship quality score (CPRS, Pianta et al., 1992)

During treatment:

- Daily anxiety VAS (daily DT score, Leclair et al., 2016; NCCN, 2025)

After treatment:

- Assessment of the radiotherapy experience and satisfaction with care with the robot, using the parent interview grid

Before the start , during and after the treatment,

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Julien, Welmant、ICM Co. Ltd.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年6月9日

首先提交符合 QC 标准的

2026年6月9日

首次发布 (实际的)

2026年6月12日

研究记录更新

最后更新发布 (实际的)

2026年6月12日

上次提交的符合 QC 标准的更新

2026年6月9日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • PROICM 2026-01 KOK

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all de-identified participants' data, the study protocol, the statistical analysis plan and the clinical study report. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.

IPD 共享时间框架

Access to study data upon written detailed request sent to ICM, from 6 months until 5 years after publication of summary data.

IPD 共享访问标准

The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅